$33.8m for renamed NeuroVista:
This article was originally published in Clinica
NeuroVista this week confirmed its name change from BioNeuronics and reported completion of a series B financing. The proceeds of the funding totalled $33.8m, which the Seattle, Washington-based epilepsy treatment technology specialist aims to channel into the continuing development of its epilepsy-based devices and clinical research programme. The principal investment was made by Advanced Technology Ventures and Delphi Ventures, while series A investors Three Arch Partners, Sprout Group and Foundation Medical Partners also contributed in the round. Epilepsy's severity is outlined by the Epilepsy Foundation which reports 2.5 million people suffer from epilepsy in the US alone, costing the government an annual $15.5 bn.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.